Anova completed enrollment of 550+ patients for an intermediate-sized, treatment IND in just six months, significantly reducing traditional site activation and patient enrolment timelines, and ...
Anova is managing the delivery of Phase 1/2a study of DB107 at UCSF, USC, UCSD and with Denovo Biopharma DB107 is a proprietary gene therapy platform for the treatment of patients with newly diagnosed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback